GHRP-2
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic growth hormone secretagogue (ghrelin-receptor agonist), marketed for anti-aging, body composition, and sleep. Its one solid effect is raising growth hormone, which supports its use as a GH-deficiency diagnostic. The fat-loss and sleep benefits people want stay speculative in humans. Being non-selective, it also raises appetite, cortisol, and prolactin, plus water retention and joint pain. Not an approved US drug, and banned in competitive sport.
Read Full recordStudied uses & evidence
Studied uses(7)
Potent growth hormone release
HighHuman trials show a large GH rise, roughly 13-fold over placebo in one study.
Diagnostic tool for GH deficiency
MediumApproved in Japan and validated in human trials as a GH deficiency test.
Appetite stimulation and orexigenic effects
HighHuman studies show increased food intake, roughly 36% in healthy men.
Evidence limits
- Evidence Level
- Moderate
Human clinical data from ~15 published studies including Phase I PK/PD in children (n=10), diagnostic studies in short-stature children (n=24), comparative endocrine studies in young and elderly adults (n=12), food intake studies in healthy men (n=7), critical illness RCT (n=33), and diagnostic evaluation in hypothalamic-pituitary disorders (n=36). Approved as diagnostic agent in Japan. Never progressed past Phase II for therapeutic indications due to reduced efficacy in GHD patients and complex side effect profile.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Active cancer
HighPotent GH secretagogue — GH/IGF-1 elevation promotes tumor growth.
Diabetic retinopathy
HighGH/IGF-1 axis activation can accelerate retinal damage.
Diabetes/insulin resistance
ModerateGH elevation can worsen blood sugar control.
Obesity with appetite issues
ModerateGHRP-2 strongly stimulates appetite via ghrelin pathway.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
Reliably increases hunger and food intake (~36%)
HighStimulates the HPA axis, raising ACTH and cortisol
ModerateStimulates prolactin release
LowGH/IGF-1 elevation causes water retention (bloating, joint pain)
ModerateCarpal-tunnel-type symptoms from fluid retention/IGF-1
LowFlushing from ghrelin receptor activation
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.